CN111405895A - 一种控释药物组合物及其制备方法 - Google Patents

一种控释药物组合物及其制备方法 Download PDF

Info

Publication number
CN111405895A
CN111405895A CN201880076792.7A CN201880076792A CN111405895A CN 111405895 A CN111405895 A CN 111405895A CN 201880076792 A CN201880076792 A CN 201880076792A CN 111405895 A CN111405895 A CN 111405895A
Authority
CN
China
Prior art keywords
pharmaceutical composition
controlled release
release pharmaceutical
drug
cellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880076792.7A
Other languages
English (en)
Other versions
CN111405895B (zh
Inventor
王立坤
王捷
马爱明
钱雯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN111405895A publication Critical patent/CN111405895A/zh
Application granted granted Critical
Publication of CN111405895B publication Critical patent/CN111405895B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating

Abstract

一种控释组合物及其制备方法。该控释组合物包括：a)含药片芯，包含活性药物；b)外包层，不含活性药物且含有至少一种遇水溶胀的基质形成剂；外包层在胃液或者模拟胃液的环境中至少4小时保持完整，后破裂释药，组合物可溶胀至足以在进食模式下胃内滞留的尺寸。

Description

PCT国内申请，说明书已公开。

Claims (30)

  1. PCT国内申请，权利要求书已公开。
CN201880076792.7A 2017-12-29 2018-12-28 一种控释药物组合物及其制备方法 Active CN111405895B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201711484309 2017-12-29
CN2017114843092 2017-12-29
PCT/CN2018/124664 WO2019129171A1 (zh) 2017-12-29 2018-12-28 一种控释药物组合物及其制备方法

Publications (2)

Publication Number Publication Date
CN111405895A true CN111405895A (zh) 2020-07-10
CN111405895B CN111405895B (zh) 2022-10-21

Family

ID=67063191

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880076792.7A Active CN111405895B (zh) 2017-12-29 2018-12-28 一种控释药物组合物及其制备方法

Country Status (3)

Country Link
CN (1) CN111405895B (zh)
TW (1) TW201929839A (zh)
WO (1) WO2019129171A1 (zh)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112294777A (zh) * 2020-11-04 2021-02-02 南京康川济医药科技有限公司 一种盐酸伊伐布雷定缓释制剂及其制备方法和应用
CN112592311A (zh) * 2021-01-03 2021-04-02 迪沙药业集团有限公司 一种硝苯地平a晶块状晶习及其控释片组合物
CN113081989A (zh) * 2021-03-29 2021-07-09 海南普利制药股份有限公司 别嘌醇缓释片剂
CN113134086A (zh) * 2020-01-20 2021-07-20 深圳市长卿医学研究院 一种降血脂的药物组合物
CN113368072A (zh) * 2021-06-23 2021-09-10 海南海神同洲制药有限公司 一种氧氟沙星包衣片及其制备方法
CN114432300A (zh) * 2022-02-16 2022-05-06 平顶山市第二人民医院 含有比索洛尔和依那普利的药物组合物及其工艺

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110483401A (zh) * 2019-09-11 2019-11-22 何琴 艾沙利酮药用盐及其制备方法和医药应用
WO2021111419A1 (en) * 2019-12-05 2021-06-10 Cadila Healthcare Limited Modified release pharmaceutical compositions of riociguat
CN113116841A (zh) * 2019-12-31 2021-07-16 广州玻思韬控释药业有限公司 胃滞留片
CN111388428B (zh) * 2020-04-14 2021-01-12 上海奥科达生物医药科技有限公司 一种托吡酯缓释制剂、制备方法及其应用
CN114053240A (zh) * 2020-07-31 2022-02-18 江苏万邦生化医药集团有限责任公司 一种薄膜包衣的片剂
US20230277467A1 (en) * 2020-07-31 2023-09-07 Jiangsu Wanbang Biopharmaceuticals Film-coated tablet
CN112315961B (zh) * 2020-11-29 2022-12-13 北京康立生医药技术开发有限公司 一种马昔腾坦硝酸异山梨酯缓释胶囊
CN114588124B (zh) * 2020-12-07 2023-10-20 江苏恒瑞医药股份有限公司 一种延迟释放的药物组合物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1960711A (zh) * 2004-03-25 2007-05-09 太阳医药工业有限公司 胃内滞留系统
WO2010064126A2 (en) * 2008-12-05 2010-06-10 Biovail Laboratories International S.R.L. Controlled release dosage forms
US20100233253A1 (en) * 2006-08-31 2010-09-16 Novartis Ag Extended release gastro-retentive oral drug delivery system for valsartan
CN102614130A (zh) * 2011-01-30 2012-08-01 江苏恒瑞医药股份有限公司 卡维地洛硫酸盐缓释制剂
US20130059003A1 (en) * 2009-12-04 2013-03-07 Dr. Reddy's Laboratories, Inc. Sustained release donepezil formulations

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1960711A (zh) * 2004-03-25 2007-05-09 太阳医药工业有限公司 胃内滞留系统
US20100233253A1 (en) * 2006-08-31 2010-09-16 Novartis Ag Extended release gastro-retentive oral drug delivery system for valsartan
WO2010064126A2 (en) * 2008-12-05 2010-06-10 Biovail Laboratories International S.R.L. Controlled release dosage forms
US20130059003A1 (en) * 2009-12-04 2013-03-07 Dr. Reddy's Laboratories, Inc. Sustained release donepezil formulations
CN102614130A (zh) * 2011-01-30 2012-08-01 江苏恒瑞医药股份有限公司 卡维地洛硫酸盐缓释制剂

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113134086A (zh) * 2020-01-20 2021-07-20 深圳市长卿医学研究院 一种降血脂的药物组合物
CN112294777A (zh) * 2020-11-04 2021-02-02 南京康川济医药科技有限公司 一种盐酸伊伐布雷定缓释制剂及其制备方法和应用
CN112592311A (zh) * 2021-01-03 2021-04-02 迪沙药业集团有限公司 一种硝苯地平a晶块状晶习及其控释片组合物
CN112592311B (zh) * 2021-01-03 2023-01-31 迪沙药业集团有限公司 一种硝苯地平a晶块状晶习及其控释片组合物
CN113081989A (zh) * 2021-03-29 2021-07-09 海南普利制药股份有限公司 别嘌醇缓释片剂
CN113368072A (zh) * 2021-06-23 2021-09-10 海南海神同洲制药有限公司 一种氧氟沙星包衣片及其制备方法
CN114432300A (zh) * 2022-02-16 2022-05-06 平顶山市第二人民医院 含有比索洛尔和依那普利的药物组合物及其工艺

Also Published As

Publication number Publication date
CN111405895B (zh) 2022-10-21
TW201929839A (zh) 2019-08-01
WO2019129171A1 (zh) 2019-07-04

Similar Documents

Publication Publication Date Title
CN111405895B (zh) 一种控释药物组合物及其制备方法
AU2008282900B2 (en) Pulsatile gastric retentive dosage forms
US20080014228A1 (en) Solid form
WO2018228441A1 (zh) 一种控释药物组合物及其制备方法
US7771748B2 (en) Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene
US20080286343A1 (en) Solid form
US20080286344A1 (en) Solid form
CN109985016B (zh) 一种非布司他的控释组合物及其制备方法
WO2008140460A1 (en) Solid form
CN1678290A (zh) 提高控释药物组合物溶解度的方法和剂型
KR20130010464A (ko) 고형 제제
ES2547141T3 (es) Composiciones que comprenden anfetamina y lisdexanfetamina
WO2011146611A1 (en) Modified gastroretentive drug delivery system for amine drugs
US9820936B2 (en) Oral controlled release pharmaceutical compositions of Bepotastine
US20130017245A1 (en) Solid preparation
WO2012020301A2 (en) Oral controlled release pharmaceutical compositions of blonanserin
EP2874610A1 (en) Multilayered pharmaceutical formulation
WO2015044375A1 (en) Pharmaceutical preparation comprising dabigatran etexilate bismesylate
TW201201800A (en) A pharmaceutical controlled release composition of losartan
WO2003075919A1 (fr) Comprime contenant du chlorhydrate de pilsicainide (voie seche)
JP2021518424A (ja) 様々な用量のレナリドミドの経口用錠剤組成物
KERALIYA et al. Formulation and evaluation of atenolol pulsatile press coated tablets using rupturable and erodible polymers
Kumar et al. Current Innovation in Layered Tablet Technology
Dalvi et al. Novel approach and current application of bilayer tablet-A review
US20050032876A1 (en) Pharmaceutical compositions comprising sumatriptan and metoclopramide, and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40031748

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant